Peroxynitrite Decomposition Catalyst Reduces Delayed Thrombolysis-induced Hemorrhagic Transformation in Ischemia-reperfused Rat Brains

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

(2014) Jonathan Emberson et al.   LANCET

Consensus Statement on the Use of Intravenous Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke by the Chinese Stroke Therapy Expert Panel

(2013) An-Ding Xu et al.   CNS Neuroscience & Therapeutics

Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans

(2013) Glen C Jickling et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Baicalin can scavenge peroxynitrite and ameliorate endogenous peroxynitrite-mediated neurotoxicity in cerebral ischemia-reperfusion injury

(2013) Mingjing Xu et al.   JOURNAL OF ETHNOPHARMACOLOGY

Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1h of cerebral ischemia and 23h of reperfusion

(2013) A. Lu et al.   NEUROSCIENCE

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

(2013) Edward C. Jauch et al.   STROKE

Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke

(2013) Shaheen E. Lakhan et al.   Frontiers in Neurology

Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury

(2012) Xing-miao Chen et al.   ACTA PHARMACOLOGICA SINICA

Matrix Metalloproteinase-2-Mediated Occludin Degradation and Caveolin-1-Mediated Claudin-5 Redistribution Contribute to Blood-Brain Barrier Damage in Early Ischemic Stroke Stage

(2012) J. Liu et al.   JOURNAL OF NEUROSCIENCE

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

(2012)   LANCET

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

(2012) Joanna M Wardlaw et al.   LANCET

Spatiotemporal evolution of blood brain barrier damage and tissue infarction within the first 3h after ischemia onset

(2012) Xinchun Jin et al.   NEUROBIOLOGY OF DISEASE

Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury

(2011) Yong Gu et al.   JOURNAL OF NEUROCHEMISTRY

Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis

(2011) D. Strbian et al.   NEUROLOGY

Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats

(2010) Yalikun Suofu et al.   JOURNAL OF NEUROCHEMISTRY

Matrix Metalloproteinase-9 as a Marker for Acute Ischemic Stroke: A Systematic Review

(2010) Maria Ramos-Fernandez et al.   Journal of Stroke & Cerebrovascular Diseases

Dissociation and Protection of the Neurovascular Unit after Thrombolysis and Reperfusion in Ischemic Rat Brain

(2009) Toru Yamashita et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Plasma and Brain Matrix Metalloproteinase-9 After Acute Focal Cerebral Ischemia in Rats

(2009) Kyung-Pil Park et al.   STROKE

Minocycline and Tissue-Type Plasminogen Activator for Stroke

(2009) Livia S. Machado et al.   STROKE

Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke

(2009) Maarten G. Lansberg et al.   STROKE

Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release

(2008) Eloy Cuadrado et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia

(2008) Wenlan Liu et al.   JOURNAL OF NEUROCHEMISTRY

National US Estimates of Recombinant Tissue Plasminogen Activator Use

(2008) Dawn Kleindorfer et al.   STROKE